• Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=9802058).
  

PubMed=9815701
Joyce Thompson, William C. Zamboni, Pamela J. Cheshire, Lois Lutz, Xiao-Long Luo, Yu-Lan Li, Janet A. Houghton, Clinton F. Stewart, Peter J. Houghton;
Efficacy of systemic administration of irinotecan against neuroblastoma xenografts.
Clin. Cancer Res. 3:423-431(1997)

PubMed=9802058
Christina R. McPake, David M. Tillman, Catherine A. Poquette, E. Olusegen George, Janet A. Houghton, Linda C. Harris;
Bax is an important determinant of chemosensitivity in pediatric tumor cell lines independent of Bcl-2 expression and p53 status.
Oncol. Res. 10:235-244(1998)

PubMed=10933967; DOI=10.1006/mthe.2000.0064
Cynthia A. Pawlik, Rekha V. Iyengar, Erik J. Krull, Stephen E. Mason, Ruchi Khanna, Linda C. Harris, Philip M. Potter, Mary K. Danks, Sylvie M. Guichard;
Use of the ornithine decarboxylase promoter to achieve N-MYC-mediated overexpression of a rabbit carboxylesterase to sensitize neuroblastoma cells to CPT-11.
Mol. Ther. 1:457-463(2000)

PubMed=11306486
Rekha V. Iyengar, Cynthia A. Pawlik, Erik J. Krull, Doris A. Phelps, Rebecca A. Burger, Linda C. Harris, Philip M. Potter, Mary K. Danks;
Use of a modified ornithine decarboxylase promoter to achieve efficient c-MYC- or N-MYC-regulated protein expression.
Cancer Res. 61:3045-3052(2001)

PubMed=28350380; DOI=10.1038/sdata.2017.33; PMCID=PMC5369315
Jo Lynne Harenza, Maura A. Diamond, Rebecca N. Adams, Michael M. Song, Heather L. Davidson, Lori S. Hart, Maiah H. Dent, Paolo Fortina, Charles Patrick Reynolds, John Matthew Maris;
Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines.
Sci. Data 4:170033.1-170033.8(2017)